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Acute and chronic exposure to benzenevapors poses anumber ofhealth hazards to humans. To evaluate the
probability thata specific degree ofexposure will produce an adverse effect, riskassessment methods mustbe
used. This paper reviews much of the published information and evaluates the various risk assessments for
benzene that have been conducted overthe past 20years. There is sufficient evidence that chronic exposure to
relatively high concentrations ofbenzene can produce an increased incidence ofacute myelogenous leukemia
(AML). Some studies have indicated that benzene may cause other leukemias, but due to the inconsistency of
results, the evidence is not conclusive. To predict the leukemogenic risk for humans exposed to much lower
doses ofbenzene than those observed in most epidemiology studies, a model must be used. Although several
models could yield plausible results, to date most risk assessments have used the linear-quadratic or
conditional logistic models. These appear to be the most appropriate ones for providing the cancer risk for
airborneconcentrations of1 ppbto10ppm,therange mostoftenobserved inthecommunityandworkplace.Of
the seven major epidemiology studies that have been conducted, there is a consensus that the Pliofilm cohort
(rubberworkers) isthebestoneforestimatingthecancerpotencybecause itistheonlyonewithgoodexposure
and incidence ofdisease data. The current EPA, OSHA, and ACGIH cancer potency estimates forbenzene are
basedlargelyonthiscohort.Aretrospective exposure assessment andananalysisofthe incidenceofdisease in
these workers were completed in 1991. All ofthese issues are discussed and the implications evaluated in this
paper. The range ofbenzene exposures to which Americans are commonly exposed and the currentregulatory
criteria are also presented.
Introduction
The health hazards ofbenzene have been the subject of
relatively widespread concern at three different times
during this century. During the 1920s, acute and chronic
toxicity among workers exposed to high levels was
reported by numerous researchers and clinicians (1-3).
During the 1970s, data indicated that benzene posed a
carcinogenic hazard to workers (4-7). In the 1980s, atten-
tion focused not only on exposure to petroleum and chemi-
cal workers but also on the concentrations to which the
public was exposed. In particular, benzene exposure via
indoor air, tobacco usage, and self-service gas stations
were of special interest (8,9). The presence of benzene in
gasoline anditsproduction duringcombustion in automotive
engines will almost certainly be well studied in the 1990s.
This paperpresents asynthesis ofrecentworkinvolving
the manyimportant issues that must be incorporated into
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a health risk assessment ofbenzene. The various assess-
mentsthathavebeenperformed overthepast20years are
evaluated and compared. The paper is organized in the
following manner: a) physical and chemical properties of
benzene, b) acute and chronic toxicityofbenzene, c) relevant
epidemiology studies that address the chronic hazard, d)
summary ofrisk assessments that have been performed on
benzene, e) current ambient exposure to benzene and the
possible risks, and]) guidelines or regulations.
Physical and Chemical Properties of
Benzene
Benzene is an aromatic hydrocarbon with the molecular
formula C6H6 and a molecular weight of 78.1 (10). Under
standard conditions,itis acolorlessliquidwithan aromatic
odor. Benzene is volatile (vapor pressure of100 mm Hg at
26°C), has a Henry's law constant of 5.5 x 10-3 atm m3/
mole (11), and is highly flammable. The limits of flam-
mability in air are 1.5-8.0% by volume and flashpoint of
-11.1°C. Benzene is relatively soluble in water (up to 1.8
g/L at 25°C) and is miscible with a variety of organic
solvents. Its density, 0.8737 g/mL at 25°C, is lower thanPAUSTENBACH ET AL.
that ofwater, so that undissolved benzene floats on top of
water. The pure liquid freezes at 5.553°C and boils at
80.10C (12).
Sources and Uses
Benzene occurs naturally in petroleum and is formed
during the combustion of biomass (13,14). Benzene,
derived from petroleum,], is a major industrial chemical.
According to Kiefer (15), approximately 1.6 billion gallons
ofbenzenewereproducedintheUnitedStatesin1990.The
major uses ofbenzene are as a component ofgasoline and
as a feedstock for the manufacture of synthetic, organic
chemicals.
In the past, benzene was used extensively as a solvent
(2). In the late nineteenth century, benzene facilitated the
rapid development of the rubber industry because of its
ability to dissolve rubber and its ease of evaporation
during the manufacture offormed or coated rubber prod-
ucts. It played a similar role in the high-speed printing
processes. Manyindustrieshaveusedbenzene asasolvent
or as a starting material for chemical.syntheses (16). Due
to toxicity concerns, benzene is infrequently used as an
industrial solvent (15).
Fate and Transport
The majority ofbenzene lost to the environment is as a
vapor (17). Benzene in the environment tends to partition
into the air (18). Once inthe air, benzene isphotodegraded
with ahalf-life ofapproximately 1 week (19). Becauseitis a
constituent of gasoline and is slightly soluble in water,
benzene has often been detected in groundwater as a
result ofleakingunderground storagetanks. The environ-
mental half-life atlowconcentrations ofbenzeneinsoiland
groundwater under aerobic conditions is approximately 10
to 20 days (20). Under anaerobic conditions, benzene is
resistant to degradation and can be present for many
years (19).
Occurrence
Benzene is a ubiquitous airborne contaminant in both
rural and urban areas. Table 1 presents some concentra-
tions of benzene typically found in the United States.
Benzene in ambient urban air is primarily due to auto-
mobile use. Other sources of benzene such as industrial
releases play a relatively minor role in determining the
ambientlevelsbutcaninfluenceairborneconcentrationsin
areas near a point source (19). For example, the ambient
concentration ofbenzene inthevicinityofgas stations has
beenreported tobeapproximately 0.005to 0.008ppm(23).
Levels as high as 0.1 ppm (21,22) have been reported.
Concentrations of benzene in the breathing zone of indi-
viduals pumping gas at self-service stations range from
about0.1 to 1ppm(21,23-26). Benzenehassometimesbeen
a groundwater and soil contaminant at hazardous and
municipal waste sites (27).
Table 1. Ambient concentrations of airborne benzene.
Locations Concentrations Reference
Middle ofPacific Ocean 10 ppt (1)
Background in urban United States 2-10 ppb (231)
Automobile interiors 10-20 ppb (26)
Ambient air in home 7-100 ppb (9)
Filling gas tank 0.1-1.0 ppm (21,24)
Toxicology of Benzene
Thewidespreaduseofbenzeneasasolventfornearly50
years has encouraged researchers to study its acute and
chronic effects on animals and humans. Numerous reviews
have discussed various aspects of benzene toxicology
(4,28-32). Various scientific bodies including the Interna-
tional Agency for Research on Cancer (IARC) (13,33), the
National Academy of Sciences (NAS) (34), the National
CancerInstitute (NCI) (35), andthe National Institutefor
Occupational Safety and Health (NIOSH) (36,37) have
reviewed the literature published through 1977.
Acute Toxicity in Animals
Asummaryofthe acute effects ofbenzene in animals is
presented inTable2.As shown, theoralLD50valuesinthe
rat vary from 3.4 to 5.6 g/kg depending on the age and
strain (38). The LD50 values are reasonably consistent
amongspecies (39).Benzeneintherabbiteyeisamoderate
irritantandcausesconjunctivalirritationand slight, tran-
sient corneal injury (40). The LC50 ranges from 10,000
ppm inmice and rats to 53,300 ppmin cats.Adultrats and
mice are often more resistant to the effects of benzene
than are young animals (41).
Acute Toxicity in Humans
Humans have demonstrated a relatively high tolerance
for acute exposure to benzene. That is, persons can be
exposed to concentrations ofbenzene up to 1000 ppm for
periodsupto 1 hrwithoutapparentseriousadverseeffects
(42). Early in the century, this characteristic encouraged
the use ofbenzene as a commercial solvent. The primary
acute responses to benzene involve adverse effects on the
central nervous system (CNS), including dizziness, giddi-
ness, exhilaration, nausea, vomiting, headache, drowsi-
ness, staggering, loss of balance, narcosis, coma, and
death (30,40). Individual case reports of acute benzene
intoxication have appeared intheliterature sincetheearly
1900s (1-3,43-46). Table 3 presents a summary of pub-
lished case reports of toxicity associated with various
airborne concentrations of benzene (47). These reports
indicate thatconcentrations ofbenzeneupto 1000ppm are
tolerable for short periods and that concentrations
between 500 and 1000 ppm are not self-limiting ifworkers
are acclimated to the odor. Moreover, for those workers
particularlyresistanttoitshematopoieticeffects, airborne
concentrations ofbenzeneinthe range of200-250ppm (8-
hr time-weighted average) may not always cause obvious
acute or subchronic toxicity. These characteristics help
explain why so many workers developed significant blood
dyscrasias and other adverse effects before 1960.
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Table 2. Results of acute toxicity studies in animals exposed to benzene (232).
Route Species Dose or concentration Results, signs or symptoms Reference
Oral Rat 3.4 g/kg LD50 (38)
Rat 5.6 g/kg LD50 (40)
Rat <1.0-5g/kg LD50 variation, age, and strain dependent (38)
Rabbit 150-300 mg/kg (2.5-11.0 pCi) Use of cold and radioactive benzene, no effect; 48.5% exhaled (95)
unchanged, 51.5% urinary excretion: 18.2-21.2% as phenol
4.8% as quinol, 4.4% catechol
Dog 2.00 g/kg Lowest reported lethal dose (233)
Intrapulmonary Rat 0.25 mL LD1oo, cardiac arrest, death (46)
instillation
Eye Rabbit 0.10 mL Irritancy, moderate conjunctival irritant, causes transient (40)
corneal injury
SC Mouse 0.088 g/kg No effect (88)
0.44 g/kg 27% Inhibition of circulatory erythrocytes (88)
2.20 g/kg 50% Inhibition of circulatory erythrocytes (88)
2.70 g/kg Found to be a teratogen (88)
Frog 1.40 g/kg Lethal dose (38)
Rat 1.15 g/kg Lethal dose (234)
Mouse 0.468 g/kg LD50 (235)
Guinea pig 0.527 g/kg Lethal dose (236)
Inhalation Rat 10,000 ppm (31.9 mg/L)/7 hr LC5() (43)
13700 ppm (43.7 mg/L) LC.(0 high levels of liver and lung congestion (23Z)
16,000 ppm (51.0 mg/L)/4 hr LC50 (29)
Mouse 2,195 ppm (7.0 mg/L) Narcosis (238)
9,980 ppm (31.8 mg/L) LC50( (239)
Rabbit 4,000 ppm (12.8 mg/L) Narcosis (240)
10,000 ppm (31.9 mg/L) Death (240)
35,000-45,000
4-71 min Slight anesthesia in 4 min and death in 22-71 min (39)
3.7 min Light anesthesia, relaxed (39)
5.0 min Excitation, tremors, running movements (39)
6.5 min Loss ofpupil reflex (39)
11.4 min Loss ofblinking reflex (39)
12.0 min Pupillary contraction (39)
15.6 min Involuntary blinking (39)
Guinea pig 36.2 min Death (38)
6,270 ppm (20 mg/L)/30 min peak Benzene blood level 3.2 mg/100 mL, 1.7 mg/mi phenol (241)
Dog 1,5675 ppm (50 mg/L)/30 min peak Benzene blood level 8.0 mg/100 mL, 1.8 mg/m3 phenol (241)
Cat 45,800 ppm (146 mg/L)
53,300 ppm (170 mg/L)
Table 3. Various reported adverse effects in humans after short-term exposure to various concentrations of benzene vapor.
Benzene concentration, ppm Duration of exposure, hr Effects observed Reference
25
50-150
500
1,500
1,500-3,000
1,550-3,100
1,570-3,130
3,000
3,000
3,000-4,700
3,130-4,700
4,650
4,700
6,190-9,300
6,200-9.300
7,500
6,200-9,300
19,000-20,000
8
5
1
1
Several hours
6
Several hours
0.5
0.5-1
1
0.5-1
0.5
0.5
Few hours
0.5-1
0.5-1
Few hours
Short exposure
None
Headache, lassitude, weariness
Symptoms of illness
Serious symptoms
Slight symptoms
No serious effects
Slight symptoms
Endurable
Dangerous
Maximum concentrations that can be inhaled for 1 hr
without serious disturbance
Maximum concentration for exposures for this period of time
Listlessness and confusion
Confusion
Definite symptoms ofpoisoning
Immediate or subsequent death
Dangerous to life
Loss of consciousness
Rapidly fatal
(43)
(43)
(43)
(43)
(42)
(242)
(44)
(43I)
(44)
(42,238)
(44)
(2)
(1)
(1)
(242)
(42,43,238)
(2)
(43,44,62,238)
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Chronic Toxicity in Animals
An increased incidence ofneoplasms has been found in
rats and mice exposed to high concentrations of benzene
by inhalation or ingestion (48-53). The sites with elevated
tumor rates include the zymbal gland, oral cavity, prepu-
tial gland, lung, and ovaries. Tbmors ofthe zymbal gland
are the most consistent tumor type reported in rodent
bioassays (48,50,54,55). In some studieswithmice, tumors
ofthe hematopoietic systemwere found butonlyin female
mice after inhalation exposure (49,56) and only in male
mice afteroral dosing(55). Thereasons forthedifferences
in response between species is not known; however, inter-
species differences inmetabolismandpharmacokinetics of
benzene via different routes of exposure may be partly
responsible (30,32,57). Thus far, no animal species tested
has clearly been demonstrated to develop the same types
ofchronic adverse effects as those seen in humans (acute
myelogenous leukemia) (52).
Chronic Toxicity in Humans
Chronic occupational exposure to benzene has been
known to cause hematological effects since the nineteenth
century. Santesson (58) described cases of benzene tox-
icity in workers fabricating bicycle tires in the late 1800s.
Many cases of benzene toxicity were reported near the
turn of the century, and Alice Hamilton warned in her
landmark paper, "The Growing Menace of Benzene (ben-
zol) Poisoning in American Industry," (2) that a serious
problem was at hand. She suggested that many workers
coulddieduetobenzene-induced anemiaifexposureswere
not better controlled.
Excessive exposure tobenzene results in suppression of
the production of both red and white blood cells, i.e.,
pancytopenia (59). More severe cases,which are generally
associated with a marked decrease in the number ofcells
in the bone marrow, are classified as aplastic anemia. One
important point is that these are not distinct diseases but
rather a continuum of changes reflecting the severity of
bone marrow damage. Among the studies that have dem-
onstrated this wide range ofhematological responses due
to benzene toxicity are those of Goldwater and his col-
leagues (60-62), as well as many others (36,63-76).
EarlyworkbyGreenburg(1) showedthatmanypersons
chronicallyexposed tobenzene cantolerateconcentrations
ofabout100to250ppmfor8hr/dayformanyyears.Table4
presents some ofthe results ofhis studies. The concentra-
tions in the work areas he studied in which benzene was
the only solvent present ranged from 0 to more than 4000
ppm. It is not known whether the values represent time-
weighted averages, although he stated thatthe concentra-
tions given are "representative ofgeneral room air and/or
air at a worker's station" (1). Hematotoxicity, defined as a
25% decrease in leukocyte count (1), was the most consis-
tentadverseeffectobserved andwasusuallyrelatedtothe
concentrations of benzene vapor. In the 1930s-1950s,
because air samplingmethodswere ratherinsensitive and
dermal exposure was often significant, red and white
blood counts were monitored as a means ofmanaging the
employee risk due benzene to exposure (47,77,78). In
retrospect, the reliance on biological monitoring rather
than air sampling probably saved many lives because it
inherently accounted for differences in individual suscep-
tibility and dermal uptake. Despite a fairly broad aware-
nessofbenzenetoxicity, Elkins (79)foundthatexposureto
concentrations ranging from 200 to 700 ppm over several
years sometimes occurred, and these resulted in some
fatalities (causeofdeathnotstated) intheleatherprocess-
ing industry during the 1940s.
Leukemia. Thethoughtthatexposuretobenzenemight
produce certain leukemias and especiallyacute myelogen-
ous leukemia (AML) was put forward in the 1950s, but
clearevidencewaslackinguntilthe1970s.AMLis acancer
in which there is an abnormal proliferation ofthe myeloid
stemcells,which arebelievedtobethecommonprogenitor
for mature circulating blood cells (i.e., erythrocytes,
thrombocytes, andleukocytes) (54). This diseaseis mostly
observed in adults and has an increasing incidence with
age, peaking in the sixth or seventh decade (80). There
have been more than 10 studies of 5 cohorts that have
shown an association between AML or its variants and
benzene exposure (70,81-85). Particularly meaningful is
the finding by several researchers of the progression of
aplastic anemiain abenzene-exposed individual through a
preleukemicphaseintofrankacuteleukemia (46,70,86,87).
Chronic studies of benzene in animals have confirmed
its hematotoxicity (28,88,89). Although numerous cases of
leukemia have been attributed to benzene exposure, there
has been a reluctance by some researchers to identify
benzene as the causative factor because no animal model
for benzene-induced leukemia has been well established.
Inaddition,itisplausiblethatbenzeneproducesthiseffect
only when other predisposing factors are present.
Aflatoxin is an example of a chemical that appears to be
carcinogenic in only a subset of the general population;
that is, cancer is seen almost exclusively in those persons
who have been chemically exposed to aflatoxin and have
had hepatitis (90).
Other Effects. Benzene has been shown to be embryo/
fetotoxic in animals, as evidenced by increased incidences
of resorptions, reduced fetal weights, skeletal variations,
and altered fetal hematopoiesis (91,92). Because these
effects only occurred after relatively high doses, benzene
has not been generally considered a significant develop-
mental hazard tohumans. There isinsufficient evidence to
indicatethatbenzeneisteratogenicorovertlyembryotoxic
inanimalsorhumansatvaporconcentrationsof10ppmfor
8 hr/day (93).
There are no data to suggest that benzene produces a
developmental hazard to humans at most workplace or
environmental concentrations. Although some epi-
demiological studieshaveimplicated benzene as adevelop-
mental toxicant in humans, their limitations are too great
to be conclusive (19). The confounding variables include
exposure to multiple substances, lack of incidences in
controlpopulationsfortheendpoints ofinterest,problems
in identifyingthe exposed populations, and lack ofdata on
the degree ofexposure.
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Table 4. The incidence ofdepression ofthe white blood cell counts in various jobs
as compared to range ofworkplace concentration ofbenzene: workers exposed to benzol.a
Benzene concentration, ppmh Incidence of
Process Ventilation Average Minimum Maximum suppression
Cement mixing' None 110 110 110 2/1
Slickeringe General room 700 500 890 0/2
Coating' Local exhaust 500' 180(1 1020(1 1/4
Mixingc Enclosed process 430(1 410" 450(1 1/3
Cement mixing' None 150 100 190 0/1
Insulating wirec None 130 50 210 6/12
210' 40d' 460(1
Compound mixing' None 1360 80 2640 1/1
580(1 220(' 880(1
Coatingc General local exhaust 130 30 410 1/10
330d1 130(1 480(1
Compound mixingc Enclosed process 100 100 100 1/3
Core painting None 220 110 340 2/5
Tire making None 150 140 160 1/9
210 50 340
Lining Local exhaust 70 50 110 0/0
90t' 0 350"
Compound mixing None 340 280 390 0/1
Cement mixing None 620 310 860 6/9
Lining Local exhaust 180 20 360 0/5
400 280 500
Dry cleaning None 1800 230 4140 2/3
Coating Local exhaust 90 40 130 1/1
Cementing None 100 80 120 2/9
aBased on work conducted in 1925 by Greenburg (1). Suppression was defined as a 25% decrease from normal count.
bAll measurements of airborne benzene were collected within the workers breathing zone with charcoal tubes during summer months and were
representative ofboth general room concentrations and work station concentrations.
'Workers were exposed to mixed solvents including benzol.
"1Measurements were taken in the winter months.
Benzene Metabolism and
Pharmacokinetics
Thepharmacokinetics ofbenzenehavebeenwellstudied
in animals. The elimination rate via exhalation has been
studied in dogs (94), rabbits (95), mice (96), and rats (97).
Schrenk et al. (94) exposed dogs to 800 ppm benzene by
inhalation. It was determined that the degree ofelimina-
tion andthe concentration in exhaled air was related tothe
duration ofexposurebecause ofthetendency ofbenzene to
accumulate in body fat. Parke and Williams (95) admin-
istered [14C]-benzene orally to rabbits and mice and
recovered approximately 43% ofthe administered dose as
unmetabolized benzene in trapped, exhaled air. Andrews
et al. (96) administered benzene to mice subcutaneously
and recovered 72% of the dose in the air. Simultaneous
treatment with both benzene and toluene (96,98) or ben-
zene andpiperonal butoxide (99)increased the excretion of
unchanged benzene in the breath. Co-administration of
these chemicals is believed to inhibit benzene metabolism,
leaving more unchanged benzene available for excretion
through the lungs.
Benzene is eliminated via excretion ofits metabolites in
theurine ofexperimental animals and only a small amount
is excreted in feces. Exhalation is the major route of
excretion of unmetabolized benzene (13). A biphasic pat-
tern ofelimination occurs in rats exposed to 500 ppm for 6
hr,with half-times forexpiration of0.7and13.1 hr(97).The
initial half-life (t,12) of 0.7 hr was similar for blood, bone
marrow, and other organs; the half-life in fat was 1.6 hr
(97). Such compartmental analyses are significantly less
useful now that physiologically based pharmacokinetic
models for benzene have been developed.
Thepharmacokinetics ofbenzenehavealsobeen studied
in humans (98,100-104). Benzene absorbed by any route is
eliminated by exhalation of unmetabolized benzene from
thelungs andbymetabolism ofbenzene intheliverand, to
a lesser extent, by the bone marrow. Metabolites of ben-
zene are excreted in the urine. The fraction of benzene
metabolized depends on the route ofexposure and the size
ofthe dose.Thefraction ofbenzene excreted intheexpired
air ranges between 12 and 50% (100,101,105). The respira-
tory elimination in humans was reported to be triphasic
(101). The initial compartment has a half-life ofabout 1 hr,
similar to the value determined in rats (97). The second,
slowerphasehas ahalf-life of3hr, andthethirdhas ahalf-
life of > 15 hr. No differences in respiratory elimination
were observed between men and women (Table 5). Gordon
et al. (106) has reported abiphasic elimination rate where,
as expected, the second phase was proportional to the
long-term body burden ofbenzene.
Metabolism
Themetabolism ofbenzenehasbeen extensivelystudied
in animals and humans (107,108). The major pathways of
benzene metabolism haveprobablybeen identified (Fig. 1).
Benzene is metabolized to a number ofchemicals that are
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Table 5. Elimination half-lives ofbenzene in rats and humans.
Species TIype Media t112, hr Reference
Rat Biphasic Blood 0.7 (97)
Bone marrow 0.7
Fat 1.6
Human Triphasic 1st compartment 0.9 (101)
2nd compartment 3
3rd compartment 15
excreted in conjugated and nonconjugated forms. Metabo-
lism occurs primarily in the liver, but in other organs as
well, including the bone marrow. Irons et al. (109) have
described the metabolism ofbenzene in rat bone marrow
that was perfused in vitro. In these studies, benzene
metabolites accumulated inthemarrowmuchastheydoin
vivo. The rate ofbenzene metabolism in marrow is much
lower than in the liver and is likely related to the low level
ofmixed-function oxidase activity in bone marrow. In the
liver (89), benzene may be converted via a cytochrome
P450-mediated pathway (110) to benzene oxide, which can
be transformed by epoxide hydratase to the 1,2-
dihydrodiol. This step leads to catechol formation (111).
Benzene oxide can also rearrange nonenzymatically to
phenol, which is metabolized to hydroquinone (112). There
isalsoevidence thatthemajorhydroxylatedmetabolites of
benzene can be formed by direct hydroxylation involving
free radical insertion (113). Quantitatively, themajormeta-
bolic product of benzene is phenol. There are a large
number of metabolites that are formed including
glucuronidated and sulfatedproducts.The neteffectofthe
metabolism ofbenzene is that the nonpolar benzene mole-
culebecomeswatersoluble andexcretable intheurine (59).
The rate of metabolism of benzene in animals and
humans is similar (allometrically scaled) and produces
many of the same metabolites. However, significant dif-
ferences in benzene metabolism among some species have
been reported. For example, Sabourin et al. (114) and
Medinsky et al. (57) have reported significant differences
between benzene metabolism in rats and mice. While rats
metabolized more benzene (orally administered) on a
weight basis than mice, mice tended to form greater
amounts of hydroquinone and benzoquinone (107,114).
Brodfuehrer et al. (115) has also shown thatwhile metabo-
lism of'4C-labeled benzene byliver slices and microsomal
preparation occurred at similar rates in tissues from
mouse, rat, and man, covalent binding of 14C-relative
metabolites to microsomal protein differed significantly
withman > mouse > rat.
The metabolism of benzene is also dose dependent.
Medinskyetal. (57) and Sabourin etal. (116) reported that
metabolism in humans was likely to be dominated by the
hydroquinone pathway for long-term exposures to con-
centrations below 10 ppm and by phenyl conjugates at
concentrations greater than 10 ppm.
The metabolism of benzene is also affected by co-
exposure to other aromatic compounds. Purcell et al. (117)
has demonstrated that co-exposures of benzene and
toluene result in a noncompetitive inhibition ofboth com-
pounds' metabolism in rats. This competition explains the
observation that co-exposure to toluene protects against
the hematopoietic effects of benzene in animals (118,119),
andreducesthe amountofbenzenemetabolizedinhumans
(120). This finding suggests that when estimating the
human risk ofexposure to benzene in petroleum products
that contain both chemicals, the approach should attempt
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to accountforthepossible effects ofcoadministrationwith
toluene and possibly other substances.
Physiologically Based Pharmacokinetic
Models
In the last decade, our understanding of the role of
metabolismintheprediction oftoxicityhasbeenimproved
by the development of mathematical models that quan-
titatively describe the uptake, metabolism, target organ
concentration, and elimination ofchemicals in animals and
humans (121-123). Such physiologically based phar-
macokinetic models (PBPK) models are useful in under-
standing the effect of route of administration on intemal
doses, extrapolation between species, and for providing a
basis for predicting the amount of the toxic metabolites
formed and their concentration at the target organ.
Travis et al. (124) have successfully described the phar-
macokinetics ofbenzene in rats, mice, and humans using a
PBPK model. Their model is based on five tissue groups,
including the liver (principal metabolic organ), fat, bone
marrow, moderately perfused organs (e.g., brain, heart,
kidney, andviscera) andthemuscle. Thebonemarrowwas
added as a tissue compartment because it is almost cer-
tainly the target organ for benzene's toxic effects, and
becauseitis apotential site ofmetabolism. In theirmodel,
benzene was assumed to be eliminated onlyby exhalation,
through Michaelis-Menten metabolism in the liver and, to
alesser extent, in the bone marrow. Metabolic products of
benzenewerenotincludedinthemodel.Modelresultshave
been successfully fitted to empirical data on inhalation,
gavage, and intraperitoneal and subcutaneous injection in
mice,rats,andhumans.ThemodelbyTlavis etal.hasbeen
used to study benzene binding to blood proteins (125), to
evaluate benzene elimination datafrombreathmonitoring
in humans (103), to determine the influence of soil on the
absorption of benzene from the GI tract (126), and to
evaluate the metabolism ofbenzene when coadministered
with toluene (117).
Medinskyetal. (57) and Bois etal. (127) have separately
developed PBPKmodels forbenzene and its majormetab-
olites. Medinsky etal. usedpublishedvalues ofphysiologi-
cal parameters and developed kinetic data by fitting the
model to data from studies in laboratory animals (27,114).
The model accounted for phenol, hydroquinone, benzo-
quinone, muconaldehyde, and other metabolites. These
models have been used to investigate the differences in
carcinogenic end points between species and the relation-
ship between route of metabolism and the administered
dose.
The Bois et al. (127) model is based on the same com-
partments and metabolites but differs from the Medinsky
et al. (57) model by using a range ofvalues rather than a
single value for the physiological parameters and kinetic
rate constants. Thevalues forthosemodelparameters are
determined by using a Monte-Carlo technique to fit data
from animal studies (127,128). Spear etal. (129) used these
models tofitexperimental datafromthreebenzene animal
studies usinginhalation (97,116) and gavage (116) to afive-
compartment model. They concluded that the model did
not adequately represent experimental outcomes of the
three studies and that, in general, parameterization of
PBPK models to obtain fits to experimental data is com-
plex and problematic (129). The Bois et al. model has also
been used to interpret the results of the benzene and
phenol National Cancer Institute (NCI) bioassays (130)
and the relative significance of short-term exposures to
benzene (131).
Hazard Identification
Disease End Points
Occupational exposure to benzene as a solvent and as a
component ofpetroleum products has been reported to be
associated with a number of different types of cancer
including leukemias, lung cancer, and Hodgkin's disease
(Table 6).
The cancers most clearly associated with workplace
exposure to benzene are the leukemias. Leukemias are a
heterogeneous groupofneoplasmsarisingfromthemalig-
nant transformation ofhematopoietic cells. Although sev-
eral agencies have concluded that benzene exposure can
increase the incidence of all forms of leukemia (13,132-
134), acute myelogenous leukemia (AML) and related leu-
kemias (collectively referred to as acute nonlymphocytic
leukemias) are the primary leukemias associated with
benzene exposure. Lamm (135) and Wong (85) have indi-
cated that AML and its variants are the only cancers
consistently associated with exposure to benzene.
While AML may have the strongest association with
benzene exposure, other cancers of the hematopoietic
system, suchaschronicmyelogenous leukemia(CML) and
multiple myeloma (MM) have also been associated with
benzene exposure (37,81,136). Both MM and CML occur
Table 6. Carcinogenic end points identified
in workers exposed to benzene.
T'ype of cancer
Leukemia
Lymphoblastic leukemia
Acute myeloblastic leukemia
Lymphosarcoma
Erythromyelosis
Erythroleukemia
Myeloid leukemia
Acute myeloid leukemia, subacute myeloid
leukemia, chronic myeloid leukemia,
lymphatic leukemia, erythroleukemia
Myeloid leukemia, chronic lymphoid leukemia,
acute leukemia, erythroleukemia
IgG myeloma
Acute leukemia, chronic lymphoid leukemia,
myeloid leukemia
Acute myelogenous leukemia
Lymphatic leukemia, myelgenous leukemia,
lymphosarcoma
Myelogenous leukemia
Acute leukemia, chronic myeloid leukemia,
chronic lymphatic leukemia
Malignant lymphoma
Multiple myeloma
Lung cancer
Reference
(86,195,242,255,267)
(243)
(224)
(244)
(46,245-248)
(249,250)
(140,159,251,266)
(252)
(253)
(254)
(46)
(6,83,84,237,257-262)
(264,265)
(159,266)
(75)
(268)
(81)
(84)
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whenthereisaproliferation ofcellsfromthesamemyeloid
stem cells as AML. This suggests that all three types of
leukemia could be caused by changes in the initially com-
mittedmyeloid stem cell. Goldstein (59)has noted thatthe
evidence forthe association between thebenzene and MM
and CML is not yet conclusive. Rinsky et al. (137) sug-
gested that MM's association with benzene exposure may
be hidden by the longer latency period for the disease.
However, the failure of the most recent update (138) to
identify additional cases of MM in the Pliofilm cohort
makes this hypothesis less tenable.
Latency
There arenumerous casereportsoflongdelaysbetween
the cessation ofknown benzene exposure and the onset of
acute leukemia (70,138-144). AML has been reported to
occur as long as 20-30 years after the last exposure to
benzene (138).
Development of quantitative estimates of latency is a
necessary aspect of low-dose extrapolation of epidemiol-
ogy data. Heretofore, most estimates of latency for ben-
zene have been based on radiation-induced leukemias
(145,146). Thelengthofthelatencyhasvariedfromassess-
ment to assessment, but the best information on latency
for benzene is probably found in the Pliofilm cohort
(147,205).
Genotoxicity
Benzene has tested negative for mutagenic potential;
however, positive results in Salmonella typhimurium
havebeen reported inthepresenceofexogenousmetabolic
activation (148,149,173). Metabolites ofbenzene have also
been identified as mutagenic (150).
There are conflicting data on the ability of benzene to
formadductswith DNA. Snyderetal. (108) reported DNA
adducts in bone marrow using a 32P-postlabeling assay
after repeated, high oral doses (1 mL/kg), while Reddy et
al. (151) was unable to find benzene-induced DNAadducts
using similar methodology. Subramangan et al. (152)
reported that bone marrow is capable of metabolizing
phenol to polymeric products which can bind tightly to
DNA. These findings suggest that positive results ofthe
radiolabeled binding studies could be due to incomplete
purification ofDNA. Finally, twobenzenemetaboliteshave
been reported to form DNA adducts after in vivo admin-
istration (153).
Benzene hasbeenreportedpositiveforvarious testsfor
clastogenicity after relatively high (in vivo) doses. Oral
administration of220-880 mg/kg benzene in mice caused
micronuclei formation (154,155). In mice, exposure to 3100
ppmbenzene for 4 hr caused increases in sister chromatid
exchanges (SCE) and chromosomal aberrations (156).
Erexson et al. (150) has reported slight but statistically
significant increases in SCEs and micronuclei in mice
after a single 6-hr exposure to benzene at concentrations
as low as 10 ppm. The sameinvestigators reported similar
small increases in micronuclei in rats after exposure to 1
ppm. Au etal. (157)reported theinduction ofchromosomal
aberrations in spleen lymphocytes of mice exposed for 6
weeks to 2 > 40 ppb benzene. The data from the two
experiments reported in this study do not agree, and the
more reliable experiment (asjudged by the authors) does
not show a dose response over a 25-fold dose range. The
animal data indicate that benzene can cause dose-
dependent clastogenesis in cells ofhematopoietic origin in
rodentsatconcentrations aslowas 1 ppm.Therelationship
between this clastogenic response and leukemogenesis in
these species is unclearbecause benzene does notproduce
leukemia in either rodent species.
The incidence ofclastogenic effects in humans exposed
tobenzene in theworkplace hasbeen examined by several
investigators. Chromosomal aberrations (CAs) or
aneuploidcellshavebeenfoundincirculatinglymphocytes
of workers who exhibited signs of hematotoxicity
(75,144,158,159). Clear evidence for clastogenicity in
humans exposed to low levels ofbenzene is not available.
Picciano (160) reported increased chromosomal aberra-
tions in workers believed to be exposed to 2-10 ppm
benzene for several years. However, a group of female
workers exposed toup to40ppmforupto 20years did not
exhibit any increases in CAs or SCEs even in a subgroup
that had decreased blood counts at the time of testing
(161). Two other studies of refinery workers and shoe-
makers (162-164) found no increases in SCEs in workers
with exposures up to 100 ppm.
Although these studies are difficult to interpret due to
possible confoundingfactors such as smoking, inadequate
exposure information, and lack of a dose-response rela-
tionship,itisreasonabletoconcludethatbenzeneexposure
at levels sufficient to cause hematotoxicity may produce
clastogenic effects in human lymphocytes. The likelihood
that these effects can occur at current occupational expo-
sure levels has not been established. The relevance of
clastogenic effects to humanleukemiais unclear, although
such effects are relevant to one of several hypothesized
mechanisms for benzene leukemogenesis discussed later.
Mechanisms ofAction
Manystudiesindicatethatbenzenemustbemetabolized
toproduceitsmajortoxiceffects (31,89,165-168). However,
the mechanism for benzene toxicity remains unclear. In
addition, the mechanisms that produce chronic hema-
topoietic effects, clastogenic effects, and leukemia are not
necessarily the same (169). Also, uncertainties remain
regarding which metabolite(s) is (are) responsible for
specific toxic effects, and it appears there maybe complex
interactions between metabolites contributing to the in
vivo and in vitro toxicity (170).
The search for a mechanism for benzene leuke-
mogenesis is greatly hampered by the absence of an
animal model for benzene-induced leukemia. Unlike most
other human carcinogens, where the evidence for an asso-
ciation between the chemical and cancer has been con-
firmed in animal studies, no good animal model for
benzene leukemogenesis has been identified. Cronkite et
al. (56) reported that benzene could induce myelogenous
leukemia in the CBA/ca mouse; however, these results
require additional confirmatory studies.
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In the absence of an animal model, plausible mecha-
nisms for benzene's leukemogenic and other carcinogenic
effects have been suggested based on indirect evidence
such as the reaction of specific benzene metabolites with
DNA and animal models of the hematopoietic effects of
benzene metabolites. Perhaps the most widely proposed
mechanism is that benzene metabolites initiate cancer by
direct reaction with cellular DNA, creating DNA adducts
that represent heritable damage to the somatic cell line.
The trans, trans-muconaldehyde (171), p-benzoquinone
(31), or even the reaction product ofp-benzoquinone and
glutathione (172) could be the causative agent. As dis-
cussed earlier, the evidence for significant formation of
DNA adducts after in vivo administration of benzene is
equivocal. Cytogenetic effects of benzene resulting in
chromosomal damage may also play an important role in
the mechanism of benzene toxicity and leukemogeneses
(174,175).
AmajorproblemwiththeproposedDNAadductmecha-
nism is the failure ofphenol to induce cancer in rodents.
The NCI bioassay ofphenol is negative (176), yetphenolis
the metabolite through which many of the suggested
binding metabolites, such as hydroquinone and p-benzo-
quinone, are formed. Bois et al. (130) concluded that the
negative phenol bioassay cannot be explained on the basis
ofafirst-pass effect as suggested by Casidy and Houston
(177,178).
An alternative hypothesis ofbenzene leukemogenesis is
thattheby-products ofmetabolismofbenzeneratherthan
the initial metabolites themselves are responsible for the
observed toxicity. This hypothesis is based on observa-
tions that benzene is metabolized by the cytochrome
P-450TTE1 (179,180) and that further metabolism ofben-
zene metabolites caninvolve avarietyofperoxidases (181).
These enzymes can produce avariety offree radicals and
activated oxygen species that may contribute to benzene
toxicity (182). This hypothesis, as well as the literature on
the oxidative metabolismofbenzene, hasbeen reviewedby
Subrahmanyan et al. (183). It is possible that both direct
and indirect mechanisms may be responsible for the
myleotoxicity and leukemogenesis of benzene. Cox (170)
has discussed these and several other proposed mecha-
nisms in a recent paper (Thble 7).
The mechanism of benzene's hematotoxicity has been
investigated in animal models by a number of authors.
Benzene metabolism has been shown to be necessary to
produce hematotoxicity. Benzene's erythropoietic effects,
asmeasuredbyinhibition of59Feuptake,isapparentlythe
result of a number of metabolites, and the interaction of
the metabolites has been shown to be signiflcant (88,108).
In vivo measurements of benzene hematotoxicity have
been demonstrated to be a function of the toxicity of
benzene'smetabolites ondividingcells (184) andhavebeen
duplicated bythe co-administration ofthebenzenemetab-
olites ofhydroquinone and phenol (185).
Bonemarrowtoxicityhasbeenshowntodependgreatly
on the timing of the exposure. When phenol and quinol
were coadministered to mice by a "continuous" dosing
regimen, bone marrowcellularity decreased initially, with
gradual recovery beginning at the second week despite
lable 7. Possible mechanisms for the
leukemogenisis ofbenzene (170).
Hypothesis 1
Benzene metabolites such as trans, trans-muconic acid or
p-benzoquinone initiate cancer by reacting with cellular DNA,
creating DNA adducts that represent hertiable, carcinogenic
damage to the somatic cell line. The resulting mutated cells fail to
respond normally to regulatory signals instructing them to
differentiate instead ofproliferating. This hypothesis is the most
common in the literature.
Hypothesis 2
The compensating proliferation ofstem cells created by cytotoxic
effects ofbenzene metabolites on partially differentiated cells
increases the likelihood of carcinogenic damage, assuming that stem
cells are at greater risk ofcarcinogenic damage while they are
actively proliferating than while they are in their normal, quiescent
state.
Hypothesis 3
Cytotoxic damage to the stromal microenvironment, including
stromal macrophages, impairs its ability to regulate stem cell
proliferation and differentiation. Initiated and/or malignant stem
cells are allowed to proliferate uncontrollably, whereas normally
their division would be suppressed or they might be stimulated to
differentiate into harmless lineages. Thus, according to this theory,
leukemia is expressed as a result offailure by the stromal
microenvironment to produce normal regulatory signals telling stem
cells to differentiate instead ofproliferate.
Hypothesis 4
Cytotoxic damage to the immune system, including lymphocytes and
stromal macrophages, allows tumor cells that would normally be
detected and killed to survive and proliferate instead, leading to a
variety ofcarcinogenic end points.
Hypothesis 5
Benzene metabolites initiate cancer through their effects on stem
cell chromosomes. Chromosomal aberrations induced by
hydroquinone or p-benzoquinone, for example, may activate
oncogenes (by carrying them to an active site as a result ofa
deletion or translocation) or inactive anti-oncogenes.
continued treatment (155). Whenthe micewere treated by
a "discontinuous" regimen, however, bone marrow cel-
lularity decreased profoundly, with no evidence of recov-
ery during the treatment period. This apparent paradox,
in which the lower total dose administered in the discon-
tinuousprotocolwasmoretoxicthanthehigherdoseofthe
continuous regimen, supports the view that the toxic
effectsofbenzenemetabolitesonthemarrowarecell-cycle
dependent. Supportive evidence for the importance of
timing on benzene toxicity is also provided by the studies
of Luke et al. (186,187), who found that a 3-day exposure
regimen produced more micronucleated polychromatic
erythrocytes than did 5 days ofexposure.
BenzenehasbeenshowntoactivateproteinkinaseC,an
enzymeplayingapivotalroleinsignaltransduction,which
is involved in cell transformation and tumor promotion
(188). A series of studies has shown that benzene affects
the function of the cellular and hormonal regulators of
blood formation, in particular, the function ofthe stromal
cell (168,189). These effects appear to be due to a selective
suppression of interleukin 1 (IL-1) released by mac-
rophages, which, in the case of the benzene-associated
suppressionofpre-Blymphocytes, resultsinareductionof
IL-1-dependentrelease ofL-4bymarrowfibroblasts (190).
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Epidemiology
The epidemiology of benzene is best defined by five
cohorts. Table 8 presents a summary of their relative
strengths and weaknesses. These studies all showed an
increase in leukemia in the exposed population, however,
most of the studies lack accurate estimates of exposure
and were confounded because persons were exposed to
several chemicals in addition to benzene.
Shoe Workers Study
Aksoy (6) conducted a case study of 34 shoe workers
who were admitted to the hematology department of
Istanbul Medical School with a diagnosis of leukemia
between 1967 and 1975. The total number ofshoe workers
in Istanbul wasestimated tobe28,500.Aksoyused data on
the leukemia mortality in the general population ofWest-
ern nations as his control population. He later indicated
that the leukemia incidence rate of2.5 to 3/100,000 forthe
general population of Turkey, which would normally be
considered the appropriate control group, was not used in
the analysis because vital statistics in Turkeycould notby
relied upon to draw scientific conclusions. The greatest
shortcoming in this study is the very poor knowledge
about the degree of exposure to benzene and other chemi-
cals. For example, it must be assumed that workers were
exposed to a number of different chemicals, including a
mixture-ofvolatile hydrocarbons, curingagents, and dyes.
The author indicated that the concentration of benzene
vapor ranged between 15 and 30 ppm outside working
hours andbetween 150and210 ppmduringworkinghours,
with maximum concentrations reaching 210-650 ppm
when adhesives containing benzene were used.
Chemical Workers
Wong (191) conducted aprospective mortalitystudyof a
group of 4602 male chemical workers from seven plants
who were occupationally exposed to benzene for at least 6
months between 1946 and 1976. They were compared to a
group of3074 male chemicalworkers fromthe sameplants
who had no occupational exposuretobenzene. The relative
risk of leukemia could not be determined in the exposed
groupcomparedtotheunexposed groupbecause nodeaths
from leukemia were observed in theinternal control popu-
lation. It should be noted that none ofthe leukemia deaths
inthe exposed exhort were ofthe acutemyelogenous type,
the cancer that has been most commonly associated with
benzene exposure in other occupational studies.
Dow Studies
Ott et al. (192) studied the mortality of594 white males
who were exposed to benzene in three production areas of
the Dow Chemical Company in Michigan. Benzene con-
centrations in the chlorobenzene, alkylbenzene, and ethyl
cellulose areas were based upon industrial hygiene
monitoringdata.Benzeneconcentrations rangedfrom0to
937 ppm, although the estimated time-weighted average
(TWA) benzene concentrations ranged from 0.1 to 35.5
ppm in the various job categories. A total of three cases
classified as leukemia was observed from 1940 to 1973
versus 0.8 expected (based upon incidence data from the
Third National Cancer Survey).
Bondetal. (83)conducted a9-yearfollow-upoftheOttet
al. (192) study and evaluated some additional workers. In
their analysis, 956 Dow Michigan division employees
potentially exposed to benzene were studied. Four leuke-
miadeaths wereobserved versus2.1 expected(based upon
U.S.whitemalemortalityrates), andthisincrease was not
statistically significant. However, all four leukemias were
of the myelogenous type. When the mortality for
myelogenous leukemia was compared with that which
would be expected based upon National Cancer Institute
Surveillance Epidemiology End Results (SEER) data, a
statistically significant excess was observed (4 observed
versus 0.9 expected; p = 0.011). Recently, Bond (193) noted
that a fifth leukemia case occurred in an individualwhose
death certificate was classified to pneumonia in the Ott et
al. study, and this subject also had AML. This study has
beenconsideredless-than-optionalforunderstandingben-
zene carcinogenicity because exposure to many other
chemicals occurred. However, it maybeuseful fordefining
the upper bound ofthe possible risk.
Chinese Worker Study
Yin etal. (84) carried out aretrospective cohort studyin
1982-83 among28,460benzene-exposed workers from233
factories and28,257controlworkersfrom83factoriesin12
large cities in China. All-causemortality was significantly
higher among the exposed (265/100,000 person-years)
than for the controls. The standardized mortality ratios
Table 8. Relative strengths ofavailable epidemiological studies.a
Cohort
Evaluation criteria Aksoy Ott/Bond Wong Rinsky Yin
Reliable benzene exposure data - -/+ - -/+
Lack ofconfounding by other chemicals - - - + +
Adequate power + - - + +
Appropriate controls - + + + +
Data available on individuals in cohort - + + +
Dose-response relationship observed - - - + +
Used accepted epidemiological methods - + + + +
a(+) Indicates that the information is adequate; (+ +) indicates that the information is good; (-) indicates that the information is poor or
nonexistent.
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(SMR) were evaluated for leukemia (SMR = 5.74), lung
cancer (SMR = 2.31), primary hepatocarcinoma (SMR =
1.12), and stomach cancer (SMR = 1.22). Leukemia was
evaluated for females only. Leukemia occurred among
some workers with as little as 6 to 10 ppm average expo-
sure and 50 ppm-years cumulative lifetime exposure.
Among the 30 leukemia cases identified in the exposed
cohort, the proportion ofsubjects with acute lymphocytic
leukemia was substantiallylower and the proportion with
acute nonlymphocytic leukemia was higher than the gen-
eralpopulation. Themajorshortcomingofthis studyisthe
lack ofreliable exposure data, adequacy ofthe nosological
methods, and the virtual certainty that exposure to other
chemicals occurred.
Ohio Pliofilm Study
Infante et al. (7) and Rinsky et al. (81,136,137) have
examined the leukemia mortality experience ofa group of
workers who were exposed to benzene in the manufactur-
ing ofrubber hydrochloride (Pliofilm) at three facilities in
two cities in Ohio between 1934 and 1974. This cohortmay
be the most intensely and carefully studied group in the
history of occupational epidemiology (7,47,77,78,81,135-
137,194-197). This group, originally described by Infante
et al. (7), contains approximately 1800 white male workers
who had been employed in the manufacture of rubber
hydrochloride for atleast 1 daybetween 1940 and 1975. In
this cohort, nine cases ofleukemia (AML) and four multi-
ple myeloma cases were observed by Rinsky et al. (136).
Follow-up studies of the cohort have identified five addi-
tional cases ofleukemia (138).
Plioflim Cohort. Since this cohortisthe one mostoften
used to estimate potency, itis important to understand its
strengths and weaknesses. While other cohorts have
larger numbers ofworkers orhavereported more cases of
leukemia, no other cohort contains such good information
onthedutiesandexposurehistories oftheworkers, northe
quality of medical surveillance. In addition, exposure to
other compounds is much less of a problem in this cohort
than in others. Detailed individualjob histories are avail-
able on all workers, and the manufacturing process
remained largely unchanged over the 40 years. Relatively
large amounts ofairsamplingdataareavailable to charac-
terize exposure levels for several time periods.
Estimates ofExposure. While the information on the
exposureoftherubberworkersisgenerallyfarsuperiorto
other epidemiology studies, there are significant short-
comings. Most of the exposure of the Pliofilm workers
apparently occurred during the 1940s, when minimal
industrial hygiene data were collected. In addition, ben-
zene exposureforspecific individuals is limited to the time
they spent in Pliofilm production. The work forces at the
two plants differed in their potential for exposure to
benzene and other chemicals while performing non-
Pliofilm tasks. The two Akron plants were part ofa large
industrial tire-building complex, and the St. Mary's plant
was in a small town in western Ohio.
Overthepast9years,threedifferentmethodshavebeen
used to estimate thelikelyretrospective exposure ofthese
workers. In the first method, Rinsky et al. (136) assumed
thatforagivenjob,workerexposurewasconstantoverthe
40 years ofoperation unless specific data indicated other-
wise. Thus, for instance,workplace concentrations ofben-
zenein1945wereassumedtobethesameasin1966. Inthe
second method, Crump and Allen (197) proposed an alter-
native analysis oftheindustrial hygiene data as described
in areportforthe Occupational Safetyand HealthAdmin-
istration (OSHA). They developed both an estimate of
cumulative exposure and peak exposure for each of the
employees. To estimate exposure for jobs during time
periods forwhich no data existed, they used all data for a
particular job to calculate a percentage of the threshold
limit valve (TLV) for that time and then applied that
percentage to earlierperiodswhen no datawere available.
Thus, if the data in the 1960s indicated that the average
exposure to benzene in a particular department was 15
ppm or 60% of the prevailing TLV of 25 ppm, then the
benzene concentration in that same department in 1945
was assumed to have the same relationship to the prevail-
ing TLV for 1960 (100 ppm) or 60 ppm. In short, they
assumed that the workplace concentration during those
timeperiods(relativetotheTLV)wouldbesimilartothose
periods when itwas not measured. Thble 9 shows howthe
benzene TLV changed during the years of Pliofilm man-
ufacture. SincetheCrumpandAllenmethodswererelated
to the TLV, their estimates of worker exposure for the
earlyyears were much greater than those ofRinsky et al.
(136).
Paustenbach et al. (47) conducted the third retro-
spective exposure assessment of these workers. Their
estimates attempted to quantitatively account for a)
uptake duetoshort-term, high-level exposuretovapors, b)
uptake due to background concentrations in the manufac-
turingfacility,c)absorptionthroughtheskin,d)morbidity
and mortality data on workers in the Pliofilm process, e)
theinstallation ofindustrial hygiene engineering controls,
f)extraordinarilylongworkweeksduringthe1940s,andg)
data indicating that airborne concentrations of benzene
wereunderestimated duetoinaccuratemonitoringdevices
and the lack ofadequate field calibration ofthese devices.
The Paustenbach et al. (47) analysis suggested that
Crump and Allen (197) overestimated the exposure of
workers in some job classifications and underestimated
Table 9. Recommended occupational exposure limits for benzene
(81,204).
Year Guideline Source
1941 100 ppm (8-hr TWA) U.S. DOL
1947 50 ppm (8-hr TWA) ACGIH
1948 35 ppm (8-hr TWA) ACGIH
1957 25 ppm (8-hr TWA) ACGIH
1963 25 ppm (ceiling value) ACGIH
1969 10 ppm (8-hr TWA) ACGIH
1971 10 ppm (8-hr TWA) OSHA
1974 25 ppm (ceiling value) OSHA
1987 1 ppm (8-hr TWA) OSHA
1989 Proposed 0.1 ppm (8-hr TWA) ACGIH
Abbreviations: TWA, time-weighted average; U.S. DOL, U.S. Depart-
ment of Labor; ACGIH, American Conference of Governmental Indus-
trial Hygienists; OSHA, OccupationalSafetyand HealthAdministration.
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FIGURE 2. Estimates of exposure histories for selected Pliofilm work categories (47).
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them for others, and that Rinsky et al. (81,137) almost
certainly underestimated the exposure of nearly all
workers.Theiranalysis concludedthatworker exposure at
the St. Mary facility was 2- to 3-fold lower (on average)
than at the two Akron facilities. In addition, short-term,
high-level exposure to benzene vapors and dermal expo-
sure was found to make a significant contribution (about
30%) to the total absorbed dose. One ofthe keyfindings of
Paustenbach et al. was that the three facilities probably
had significantly different airborne concentrations ofben-
zene; especially during the 1940s and 1950s. Figure 2
graphically compares the results of the three exposure
estimation methods for three different job categories at
the two different manufacturing locations.
The Paustenbach et al. (47) estimates indicate that the
highest exposures tobenzeneoccurred duringthe1940sin
theAkron Iplant. Before the1940s, the shorterworkweek
and lower production volume probably kept the doses
relatively low. After the 1940s, the improved engineering
controls at the St. Mary's and Akron II plants and the
increasing concerns about the toxicity of benzene (as
reflected in the decreasing TLVs) apparently brought
about reductions in the workplace concentrations. During
thisperiod, St. Maryworkers hadgreatlyreducedlevelsof
exposure due to a reduction in Pliofilm production at
that site.
Paustenbach et al. (47) acknowledged that because
there were virtually no measurements taken during the
1940s, there is significant uncertainty in their estimates.
However, they were confident that their estimates are
more likely to be accurate than prior estimates for several
reasons. First, they found and used new information not
considered by the earlier investigators. Second, based on
whatis known abouttheincidence ofleukemia atthe three
plants (based on the cumulative doses), the correlation of
disease with the dose predicted byPaustenbach et al. was
better than using either the Crump and Allen or the
Rinsky et al. methods (Table 10). Finally, Paustenbach et
al. take issue with the claim (199) that data on which the
revised estimates were based had been fully analyzed
during the earlier OSHA hearing on establishing a per-
missible exposure limit (PEL). Several key findings in
Paustenbach et al. were in fact notidentified in the OSHA
regulatory action. Among these are the St. Mary's shut-
down during the 1940s, the exceedingly long work sched-
ules, and an attempt to address dermal uptake.
Petroleum fransportation and Distribution
Workers Study
A large epidemiology study of workers exposed to
petroleum products (containing benzene) has recently
been completed (85). The study reported a statistically
nonsignificant excess of AML in land-based distribution
workers that was not correlated with total hydrocarbon
exposure. A shortcoming of the study is that it did not
determine benzene concentrations but only exposure to
total petroleum hydrocarbons. An estimate of the con-
centration of benzene vapors could be made with some
degree ofconfidence; however, this analysis has yet to be
conducted.
Rushton et al. (198) and Schnatter et al. (200) also
recently reported the results of similar studies of
petroleum product distribution workers in the United
Kingdom and Canada. Both reports indicated that AML
SMRs were slightlyelevated; however, the increases were
not statistically significant.
Evaluating Benzene's Cancer Dose-
Response Curve
It is unlikely that any specific case of environmental
leukemia can be directly related to exposure to very low
concentrations ofbenzene (or anychemical), norisitlikely
that an animal experiment (alone) can describe the rate of
response at low doses. Consequently, low-dose extrapola-
tion models must be used to predict the probability of
disease. The method or model used to estimate the leuke-
Table 10. Pliofilm leukemias by location, type, and estimated cumulative exposure (138).a
Cumulative exposure, ppm-yr
Plant location Year first exposed Type ofleukemia Rinsky Crump Paustenbach
Akron 1 1939 AML-C 474 937 900
1941 AGL 639 2150 1420
1942 AML-C 98 306 668
1942 AML-B 252 324 1120
1944 AML-G 497 1490 1000
1945 AML-C 259 251 1050
1948 AML 1 15 533
Akron 2 1950 CML 90 65 336
St. Mary's 1940 Monocytic 50 379 116
1940 ALL 62 144 291
1945 Unspecified 7 50 11
1948 CML 0.1 3 3
1949 Unspecified 1 7 9
1950 Myelogenous 10 23 54
Abbreviations: AML, acute myelogenous leukemia (AML-C, cystic; AML-B, blastocystic; AML-G, granulocytic); CML, chronic myelogenous
leukemia.
aWhite male "wetside" employees through1987.
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Table 11. Overview ofapproaches to benzene low-dose extrapolation and potency.
EPA (145) California (201) Thorsland (146) ACGIH (204)
Cohort Rinsky et al. (81); Ott et Rinsky (Rat Rinsky (81) Rinsky (80)
al. (182); Wong et al. (51,53,54,55) and Rinsky
(191) et al. (81); Ott et al.
(192); Wong et al. (191)
Disease end point All leukemias All leukemias Acute myelogenous All leukemias
leukemia and aplastic
anemia
Low-dose extrapolation Linear Linear (95th confidence Linear-quadratic Conditional loglogistic
model limit)
Risk-specific dose (10-6) 37 ppta 25 ppta 1-10 ppba 100 pptb
aASsumes exposures of24 hr/day for a 70-year lifetime.
bAssumes that persons are exposed for 8-hr/day, 5 days/week, for 30 years.
mia risks due to exposure to low doses of benzene has a
significantimpactonregulations. Changesintheincidence
of disease or in the estimates of exposure tend to have
much smaller effect on the risk estimates than the low-
dose model selections.
The impact of model selection is well illustrated by
comparing the currently published cancer potency esti-
mates forbenzene. The different potencies predict signifi-
cantly different acceptable concentrations for the same
risks. These differences are in part due to the choice of
epidemiology data but are largely a function ofthe model
selected. Table 11 presents a summary ofthe assumptions
used in the various models and the concentration ofben-
zene, which corresponds to a predicted excess lifetime
cancer risk of 1 in a million.
Current Federal policies require that human data be
used instead of animal data if the human data are suffi-
cientlyrobust. The epidemiology studymost often used to
estimate the human risk of exposure to benzene -is the
rubber workers cohort (7,81,136,137). Many different
extrapolation models have been applied to these data to
identifysafelevels ofexposure.AsshowninTable11,linear
models were used by the Environmental Protection
Agency (EPA) and OSHA in the early 1980s. A modified
form ofthe linearized multistage was used by Crump and
Allen (197) andbythe EPA(145).Thorslundetal. (146)also
developed arevised estimate in 1988. In1987, Rinskyetal.
used aconditionallog-logisticmodeltopredicttherisk.As
of1993, none ofthese models hasbeenidentified as clearly
superior to the others.
Early Regulatory Assessments
Benzene was one of the first epidemiologically based
riskassessments conductedbythe EPA(133). TheAgency
based its evaluation upon the disease data on the Pliofllm
rubber workers and the Dow cohorts. Cumulative dose,
defined simply as the product of concentration and expo-
sure duration, was the index ofexposure. The EPAused a
linear nonthreshold model to estimate risk. The results,
based on these studies, indicated that the 95% upper-
bound estimate of the probability of developing leukemia
in excess ofbackground rates following aworking lifetime
ofexposureto 1 ppmofbenzenewas14.9per1000basedon
the rubber worker data and 46.4 per 1000 based on the
Dow data (133).
White et al. (82,202) conducted the next assessment of
benzene. Acumulative dosewas again used to predictrisk
based on the Pliofilm and Dow cohorts. In deriving their
exposure measures, it was assumed that occupational
exposures were at the TLV concentrations at the time of
the exposure. In their analysis, workerswith fewerthan 5
years ofwork experience were excluded. A simple one-hit
modelwas used topredict the response. For exposure to 1
ppm, 8 hr/day, for 30 years, they predicted 3-11 excess
leukemia deaths per 1000 persons (based on the Pliofilm
cohort) and 3-10 excess leukemia deaths per 1000 persons
(based on the Dow cohort).
In1984,CrumpandAllen(197)developedanassessment
based on the work of Bond, the Pliofilm cohort, and the
original Dow cohorts (192). They also evaluated a number
of dosimetrics for predicting risks, including cumulative
dose, weighted cumulative dose, window dose, and peak
exposure dose. The cumulative dose is the same exposure
measure used by EPA in 1979 and byWhite et al. in 1982
(82). The weighted cumulative dose gives no weight to
exposures within the most recent 2.5 years and pro-
gressivelylessweightto exposures that occurredoverthe
past 7.5 years. The window dose considered exposure in
the 10-year window defined by 2.5 and 12.5 years in the
past and the peak exposure dose measured all cumulative
exposures that exceeded 100 ppm. The time intervals of
2.5, 7.5,and12.5yearswereselectedbased ontheleukemia
rates and the time oftheir appearance in persons exposed
to radiation due to the bombing in Nagasaki and
Hiroshima.
Crump and Allen (197) used two mathematical
approaches, the relative risk and the absolute riskmodels,
to evaluate the relationship between leukemia risk and
exposure. The relative risk model assumes that incremen-
tal risk due to exposure to benzene will be proportional to
the background mortality in the group. The absolute risk
model assumes that the additional risk associated with
dose is the same for all age groups. A relative risk model
using cumulative dose and based on the combined rubber
workers and Dow cohorts predicted 7.5 excess leukemia
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deaths per 1000 workers exposed to 1 ppm for 40 hr/week
for 30 years. An absolute risk model predicted two excess
leukemia deaths per 1000 workers for the same dose.
The authors expressed a preference for the cumulative
orweighted cumulative exposure approach because ofthe
leukemia experience in Japan. They noted "window expo-
sures allow the risk [of leukemia death associated with
benzene exposure] to disappear completely after 15 years,
which appears tobe atvariancewiththeJapanese data[on
leukemia latency]" (197). The utility ofthe peak exposure
dose was examined by the authors in further analysis of
the Pliofilm cohort. In a separate analysis ofpersons with
200-plus ppm-year cumulative exposure, workers exposed
to benzene at levels less than 100 ppm were found to have
higher relative risks than workers with exposures greater
than 100 ppm. In light of this finding, this approach was
not considered credible.
EPA Assessment
Overthepast20 years, the EPAhasdeveloped quantita-
tive unit cancer risk estimates for nearly 150 known or
suspect carcinogens using a single methodology (203).
However, the standard procedure was not used when the
agency evaluated benzene (145). Instead, EPAadopted the
models developed originally by Crump and Allen. EPA
derived a cancer risk estimate from data obtained in three
different epidemiologic studies on workers exposed to
benzene vapors (81,191,192). Using an average derived
from the application of several models, EPA predicted a
risk of2.6 x 10-2for exposure to 1 ppmbenzene for a24hr/
day, 70 year-lifetime [equivalent to 0.029 mg/kg/day for
lifetimeexposure]. Usingthis estimated potencyvalue,the
airconcentration associatedwith an excess risk of10-6 was
40 ppt. Since this estimate was developed, two updates of
the cohort have been released [Rinsky (136) and Paxton
(138)]; however, EPA has not yet had an opportunity to
revise its risk assessment to incorporate the results.
Rinsky et al.
Rinsky et al. (136,137) developed an assessment of
occupational exposure based on a conditional logistic
model and additional follow-up data on the rubber worker
cohort. The conditional logistic model differed from the
assessment of White (82) and Crump and Allen (147) in
several ways. Specifically, the assessment was based only
on the rubber worker cohort and used a novel dose-
response model. In their assessment, Rinsky developed
detailed estimates ofworker exposure that differed from
the estimates made by Crump and Allen (197). Based on
theresults oftheanalysis,theyrecommendedloweringthe
occupational standard forbenzene to 0.1 ppm. In 1990, the
American Conference ofGovernmental Industrial Hygie-
nists (ACGIH) TLV committee proposed lowering the
TLV from 10 to 0.1 ppm (204). They plan to reach a final
decision on the most appropriate value in 1993 or 1994.
Thorslund et al.
A detailed reanalysis of the benzene cancer potency
factor was performed in 1988 byThorslund et al. (146,147).
This reanalysis was based on the rubber workers cohort
and considered data from the 1981 update of the disease
incidence. The reanalysis also attempted to estimate
workers' exposures on anindividualbasis and did notlump
workers into dose groups. Finally, Thorsund et al. exam-
ined rigorously the dose-response relationship in the
cohort. The objectives of the evaluation were to test
whethertheupdate ofthecohortandbetter use ofexisting
exposure data would result in a significantly different
estimate ofpotency andwhetherthe datafrom the rubber
worker cohort was best fit by a linear or nonlinear dose-
response model.
The effect ofthe various modifications in the reanalysis
are presented in Table 12. Two modifications (taken
together)had arelativelymajoreffect onthelinearmodel's
estimates: use of a more refined latency distribution to
obtain the exposure weighting function, and use of
rigorous statistical techniques that relied on individual
exposure estimates and time-to-tumor data, to estimate
the transition rate. Thorslund et al. (146) concluded that
usingthese moreplausible assumptions, the linearmodel's
estimate of potency was overestimated by approximately
one order ofmagnitude.
Thorslund et al. (146) also concluded that there was
significant evidence thatthe dose-response curve forben-
zene and AML was better fit by a nonlinear rather than a
linearmodel. Theyrecommended using a quadraticmodel.
Thorslund et al. (146) also developed a model which had
both a linear and a quadratic term. The results of the
model were dictated by the quadratic term at high
(occupational) exposure levels and by the linear term at
low (environmental) exposures. Both of these models
Table 12. Effect ofmodifications of EPA's assumption on estimates
of cancer potency for benzene (146).
Excess risk at
1-ppm continuous
Modification lifetime exposure
None 2.60 x 10-2
Model restricted to absolute risk and weighted 1.76 x 10-2
cumulative dose form; data restricted to Rinsky
cohort
Three years offollow-up added 1.71 x 10-2
Job code errors corrected 1.84 x 10-2
New weighted cumulative dose form from 3.19 x 10-3
epidemiological latency data; new statistical method
for estimating transition rate parameter
New definition of disease induced by benzene; new 3.48 x 10-'
estimate ofbackground rates in U.S. population
Quadratic model 1.43 x 10-4
Linear-quadratic model 1.00 x 10-
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resulted in lower estimates of potency than the linear
model (Table 12).
Thorslund et al. (146) concluded that the quadratic
equation is the best one for predicting the leukemia risk
observed inthe Pliofilm cohort. This conclusionwasbased
on a) theempirical fit ofthe datato the quadratic equation
and b) biological evidence that a two-hit mechanism (i.e.,
two molecules ofbenzene or its metabolites must interact
with a cell's DNA to initiate cancer) is more likely than a
one-hit mechanism. The linear-quadratic model, which is
based on a conservative assumption about how back-
ground factors mayinfluence the probability thatbenzene
canproduce leukemia, was also presented as a reasonable
maximum upper bound ofbenzene risk.
Because the dose-response model used by a regulatory
agency has significant policy and regulatory implications,
a conference was convened in Georgetown in 1989 to
evaluate the reanalysis (147,205). At that workshop, par-
ticipants considered the linear quadratic model for
estimating the leukemogenic risks ofbenzene to be more
appropriate than the one-hit model. The participants also
concluded that a constant relative risk model was not
applicable for benzene-induced acute leukemias because
the Rinsky cohort does not show a constant relative risk
for acute leukemias as the cohort ages. Furthermore, they
concluded that the use of the absolute risk rather than
relative risk model is consistent with the EPA's policy
regarding the interpretation ofanimal data. The George-
town workshop (205) recommended that the human data
be fitted to other two-stage models and that a sensitivity
analysis be performed on models such as the two stage,
quadratic, and linear-quadratic, as well as the 1985
EPA model.
Reanalysis of Rubber Worker and Dow
Studies
Austin et al. (206) surveyed the evidence for benzene
toxicity, examined previous risk estimates, and provided
an updated risk assessment using the rubberworker and
Dowcohorts. These authors modeled thenumber ofexcess
leukemia deaths associated with various exposure levels.
Their model was based on the assumption that "the pro-
portional excess leukemia mortality observed during the
follow-up period will continue until all cohort members
have died" (206). Using this risk estimation model and a
target cumulative exposure of30ppm-years (1 ppm, for40
hr/week for 30 years), 51-83 excess leukemia deaths per
1000 exposed were predicted based on the Pliofilm cohort
and 47 excess leukemia deaths per 1000 exposed were
predicted based on the Dow cohort.
Brett et al.
Brett et al. (207) conducted a risk assessment that was
to a large degree a sensitivity analysis of Rinsky et al.
(136). Theyagreedthatthe rubberworker cohortprovided
the best basis for estimating the risk ofleukemia and that
no other epidemiology study is as appropriate. They
showed that the Rinsky model was fairly sensitive to the
estimates of employee exposure. For example, when the
exposure estimates developed by Crump and Allen were
applied to their model, the risks associated with 1-ppm
(working lifetime) exposures decreased significantly.
Brett et al.'s reevaluation of the data indicates that past
assessments may have overestimated the cancer risk by a
factor of3-24. Based on the data ofRinskyet al. (136) and
exposure matrices of Crump and Allen (197), a risk esti-
mate of 7.9 excess leukemia deaths per 1000 workers
exposed to 10 ppm for 45 years and for those persons
exposed to 1 ppm for 45 years might have an excess of0.5
leukemia deaths per 1000.
Paxton et al.
Paxton et al. (138) evaluated the impact of the recent
update ofleukemias in the rubberworker's cohort and the
new the exposure estimates of Paustenbach et al. (47) on
thedose-response curves. Theyfound thattheupdate and
the new exposure estimates gave further support to the
risk estimates proposed by Brett et al. (207). The study
also concluded that because no cases of leukemia are
observed in workers who started employment after 1950,
the observed increase in leukemia may be the result of a
threshold response toveryhighlevels thatoccurred inthe
early years ofthe manufacturing process.
Human Exposure
Dermal Uptake
Benzene is readily absorbed through the skin of man
(208,209) and animals (210-212). In general, studies in
humans suggestadermaluptakerateintheforearmof0.4
mg/cm2-hr (209). Paustenbach et al. (47) suggested that
under certain occupational circumstances, dermal absorp-
tion canmake a signifiecant contribution (about 10-25%) of
the worker's total uptake.
In contrast to liquid absorption, the dermal uptake of
benzene from contaminated soil has been modeled by
McKone et al. (213) and Burmaster et al. (214). They
showed thatbenzene is poorly absorbed from a soil matrix
and that even underideal conditions (extensive contact for
long periods oftime), less than 10% ofbenzene in soil will
be absorbed by the skin.
Occupational Exposure
Occupational exposure to benzene involves airborne
concentrations that are 100- to 1000-fold greater than
environment levels. Occupational exposure to benzene has
decreased greatly over the past 40 years as a result of
lowering occupational exposure limits like the TLVand by
discontinuing the use of benzene as a solvent. Currently,
significantexposure tobenzeneislimitedtotheworkersin
the petroleum, coal (coking operations), and synthetic
organic chemical industries. Under the current OSHA
PEL, workplace exposures may not exceed 1 ppm. In the
petroleum industry, 8-hr TWA exposures are generally
kept below 0.3 ppm (215). Dermal exposure to benzene in
the petroleum industries is generally controlled under
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OSHA requirements; however, dermal exposure to gas-
oline and benzene in small workplaces (less than 10
employees) can be significant due to less stringent indus-
trial hygiene practices.
Community Exposure
Due to the ubiquitous presence of benzene in the
environment, the general population is exposed daily to
varying levels of benzene. Iypical sources of exposure
include cigarette smoking, use of certain consumer prod-
ucts, inhalation of indoor and outdoor air, pumping gas-
oline (self-service gas stations), and riding in an
automobile (8). During the 1980s, EPA performed exten-
sive investigations (the TEAM studies) of the general
population's exposure to volatile organic compounds such
asbenzene (8,9,216,217). TheTEAM studiesfoundthatthe
mostimportant source ofexposure forthe general popula-
tion is mainstream cigarette smoke inhaled by smokers.
The source accounted for 39% of the total uptake of
benzene in the U.S. population (9). In addition, environ-
mental tobacco smoke (ETS) contributes an additional 5%
ofthe nation's exposure. The second largest source (20%)
of nationwide exposure is attributed to various personal
activities, which include exposures related to automobile
use. Atmospheric emissions (auto exhaust and industrial
emissions) account for only about 20% of total exposure
(Fig. 3).
A number of sources sometimes considered important,
such as petroleum refining operations, petrochemical
manufacturing, oil storage tanks, urban-industrial areas,
service stations, certain foods, groundwater contamina-
tion, and underground gasoline leaks, appear to be rela-
tively unimportant on a nationwide basis (9).
The TEAM studies finding that smoking is the largest
source of human uptake of benzene is consistent with
chemical analyses ofcigarette smoke. Loforth et al. (219)
measured an average of500 pgofbenzene produced from
anindividual cigarette. Westeretal. (220) andWallace and
Pellizzari (217) also reported that average benzene breath
levels of smokers are significantly elevated over non-
smokers.
Industry (14%)
l _ _~~~~Pesonal
AutDs (82%)
Elevated levels of benzene in indoor air represent an
additional source of exposure. Wallace et al. (8,9,216,217)
reported the results of the EPA TEAM studies that
benzene levels in the home are generally elevated over
outdoor levels. These elevated concentrations are largely
due to ETS, use ofpetroleum products, and other sources
(9,221).
Althoughbenzeneisrelativelysolubleinwater(1.8g/L at
25°C), the potential for human exposure through water
consumption is limited. Benzene's volatility and bio-
degradability results in low levels in surface water (17,18).
Levels of benzene in public drinking water supplies are
nondetectable generally (>0.5 g/L). Benzene can be a
contaminant in shallowgroundwaterduetoleakingunder-
ground storage tanks, but the number of individuals
affectedbysuchcontaminationis small. Underthecurrent
EPA drinking water standards, benzene levels in public
water supplies cannot exceed 5 jg/L.
Benzene hasbeenreported as alow-level componentofa
large number of foods,(35,222). NCI (35) estimated that
many Americans currently ingest as much as 250 pLg/day
from their diet. However, a recent studyperformed bythe
American Petroleum Institute contradicts these findings.
The study examined foods that the literature indicated to
contain significant amounts ofbenzene. Benzene levels in
these foods were found to be eitherverylow ornondetect-
able. Based on these results, the American Petroleum
Institute (API) concludedthatbenzeneisunlikelyto occur
in food at levels of toxicological significance (201). This
finding is consistent with analyses of the TEAM studies
data that concluded that 99% ofbenzene exposure occurs
via inhalation (9). Travis (18) also concluded that based on
the physicochemical properties of benzene, diet was
unlikely to be a significant source of exposure.
Although benzene is now rarely used as a bulk solvent
(15), trace levels of benzene can still occur in certain
consumer products. Wallace (9) reported that 400 of
approximately 5000 materials and products tested by the
National Aeronautics and Space Administration (NASA)
werefound to emitbenzenevapors inconcentrations rang-
ing from 0.01 ppm to 140 ppm. These products include
paints, adhesives, pens, rubber products, carpeting, liquid
Exposures
ETS (5%)
Autos (18%)
_ llq ||..H' tt3N! "l Cigarettes (39%)
Personal (18%)
Emissions
Home (16%) Industry (3%)
FIGUJRE 3. Benzene emissions versus exposures for the Los Angeles basin (218).
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detergent,furniturewax, andbuildingmaterials.Asurvey
ofproducts containing volatile organics found that a simi-
lar percentage ofproducts contained low but measurable
amounts ofbenzene (223).
TEAM data have shown that the major sources of
emission of benzene are not necessarily the most signifi-
cant sources of human exposure. For example, indoor air
concentrations of benzene are significantly higher than
outdoor concentrations (217). Figure 3 presents a com-
parison ofthe air concentrations in the Los Angeles area
and the sources of exposure (218). Autos and industry
contribute (96%) tothe outdoorairborne levels ofbenzene,
but human uptake of benzene is determined primarily
(79%) by cigarettes, indoor air, and personal factors.
Risk Characterization
Table 13 presents an analysis by Wallace (9) on the
magnitude of risks offered by exposures to various
sources ofbenzene. His estimates are based on the cancer
potency models used currently by EPA (145). For com-
parison purposes, the risks from acceptable levels ofben-
zene in public drinking water supplies exposures also has
been included.
These estimates ofpopulation risks indicate that while
occupationalexposure mayinvolverelativelyhigh airborne
concentrations ofbenzene, thebulkofbenzeneupdate and
risk results from nonoccupational exposures. Smoking is
the dominant source ofbenzene exposure and risk. How-
ever, Wallace estimated thatnonsmoking, nonoccupational
benzene exposures result in some 400 cancer cases per
year. As Table 11indicates, estimates ofriskfrom benzene
vary considerably among published risk assessments.
Using the linear-quadratic model ofThorslund et al. (146)
for example, results in an estimate ofnonsmoking, nonoc-
cupational risks of less than 10 per year in the United
States.
Regulatory Issues
Occupational Exposure Limits
Recommendations to limit exposure to benzene in the
workplace came soon after the hazard posed by benzene
toxicity was recognized. Serious episodes ofbenzene tox-
icity in the rotogravure printing industry in New York
(224) were in part responsible for the setting of occupa-
tional standards forbenzene,whichwererecommendedby
thenewlyformedACGIHinthelate1930s andearly1940s.
Table 13. Benzene exposures and theoretical risk in United States.
Activity Intake (,ug/day) Cases/year
Smoking (9) 1,800 500
Passive smoking (9) 50 50
Outdoors (9) 120 150
Driving car (9) 40 40
Filling gas tank (9) 10 5
Occupational (9) 10,000 10
Other personal (9) 150 200
Drinking water at the 10 0.01 (17)
current MCL (229)
The ACGIH establishes TLVs that are voluntary guide-
lines and do not carry the force of law; however, many
industries have historically attempted to comply with
them.
Table 9 shows how benzene standards changed over
time. In 1971 the OSHA standard was reduced to 10 ppm
and by 1974, when OSHA and the National Institute of
OccupationalSafetyandHealth(NIOSH) suggestedaddi-
tional regulations, the 10 ppm TWAstandard was comple-
mented with a 25-ppm ceiling value (36). In 1976, OSHA
and NIOSH reached the conclusion that benzene was a
leukemogen and thata10-ppm standardwas notsufficient
to protect workers (207). In 1977, OSHA first proposed
lowering the occupational benzene standard from 10 ppm
to 1 ppm on the basis ofits qualitative assessment ofthe
leukemia risk. Their permanent standard was not, how-
ever, supported by the U.S. Supreme Court on the basis
that OSHA had not demonstrated that a significant risk
existed at the previous 10-ppm standard (149). In 1987,
OSHAsetthestandardat1 ppmforan8-hrday(TWA)and
5 ppm for 15 min (134). NIOSH (132) recommended that
the occupational exposure standard for benzene be
revised to a 10-hr TWA of0.1 ppm with a 15-min ceiling
value of 1 ppm.
In 1991, the ACGIH proposed that benzene be listed on
the Chemical Substances TLV Notice of Intended
Changes of 1990-1991 at 0.1 ppm as a TWA with a skin
notation and designation as a Al carcinogen (confirmed
human) (204). The recommended TLV of 0.1 ppm is less
than the concentration associated with genetic damage in
animals (150) and is less than the concentrations associ-
ated with genetic damage in human beings (161). Because
calculations show that the dermal absorption of benzene
can contribute substantially to thetotal absorbedbenzene
dose (208,209), the skin designation was retained.
This proposed reduction is under considerable debate.
Paxtonetal. (138)has shownthattheoriginalcarcinogenic
risk assessment (137) considered by ACGIH likely over-
estimates carcinogenic risks. Currently, Infante and oth-
ers question this conclusion and believe the 0.1-ppm value
is necessary to provide adequate protection.
Air Toxics Regulations
The EPAhas regulatedindustrial emissions ofbenzene
underthe CleanAirAct'sprovision forthe National Emis-
sion StandardforHazardousAirPollutants (NESHAP) in
1981 and again in 1988 and 1989. These regulations have
focused on the petroleum, chemical, and steel industries
(225-227).
Under the revised Clean Air Act of 1990, emissions of
benzene and other toxins from industrial sources will be
controlled usingtechnology-based standards. In addition,
the maximum concentration ofbenzene in gasolinewill be
limited to 1% by volume. In addition to the direct regula-
tion ofbenzene emissions, regulations that control hydro-
carbonemissions alsohavereducedthe amountofbenzene
emitted by stationary sources.
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Drinking Water
In 1985, the EPA Office of Drinking Water proposed
setting the maximum contaminant level (MCL) for ben-
zene in drinkingwater at 0.005mg/L (228). This standard
was promulgated in 1987 (229). Because of benzene's
known carcinogenicity, EPA's Office of Drinking Water
has set the maximum contaminant level goal (MCLG) for
benzenein drinkingwaterat0(229). The MCLGcannotbe
enforced. The Office of Drinking Water used the EPA
estimates of benzene's carcinogenic potency to estimate
the benzene concentrations in drinkingwater that corres-
pond to carcinogenic risks of 10-4, 10-5, and 10-6. The
concentrations were 68, 6.8, and .068 ,ug/L, respectively
(229). In the 1980s, the National Research Council (NRC)
(230) derived a short-term seven-day standard of12.6mg/
L for benzene in drinking waters using the data of Wolf
et al. (40).
Conclusion
Although several hundred papers have been written
over the past 50 years about the health hazards posed by
benzene, we are not yet able to precisely identify the
cancer potency factor for humans. There are several rea-
sons for this: first, insufficient time has passed to allow a
complete determination of long-term effects in the key
occupationalcohorts; second,wearenotcertainwhichlow-
doseextrapolationmodelislikelytogivethemostaccurate
estimate ofrisk. As has been noted in the assessment of
many carcinogens, the estimates generated by currently
accepted dose-response models are generally the max-
imum plausible ones and the actual risk at low doses may
be zero. Athird problemisthe absence ofan animalmodel
of benzene leukemogenesis, which prevents the direct
investigation ofthe mechanism forbenzene's carcinogenic
effects in humans.
Fortunately, moreandbetterinformationisbeingdevel-
opedonthemetabolismofbenzeneinhumans andanimals,
and it is hoped that PBPK models will allow us to quan-
titatively understand the likely human health hazard at
low doses. Information on metabolism and indirect infor-
mation on the likely mechanism of action, coupled with
betterestimates ofexposureforthecohortsbeingstudied,
would be able to provide more accurate estimates of the
cancer risk at doses to which the general population is
being exposed currently. Until then, it is likely that the
EPAand otheragencieswill choosetoregulatebenzene in
ambient air based on the incidence data from the rubber
worker's cohort, the most recent exposure estimates for
thatgroup, andmodels that areconsidered mostappropri-
ate for benzene and/or for leukemia.
Thanks are given to Carol Gillis, Peter Beatty, Peter Craig, and
Richard Russell for their review ofthe paper.
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